Batscout
New member
Tirzepatide: Zepbound and Mounjaro patents
- Composition of Matter Patent (US 9,474,780): This key patent protects tirzepatide's specific molecular structure and its dual-agonist design. It features critical structural tweaks (like the addition of aminoisobutyric acid and a C20 fatty acid chain) that allow the drug to bind to both GIP and GLP-1 receptors and last for a week in the body. This primary patent expires in January 2036. [1, 2]
- Formulation & Manufacturing Patents: Eli Lilly and Company holds secondary patents regarding the drug's stability, delivery methods, and injection solutions, which can extend patent protections out to June 2039. [1, 2]
- Regulatory Exclusivity: Because tirzepatide was designated as a New Chemical Entity (NCE), it is granted a statutory period of FDA exclusivity that generally prevents any other manufacturer's identical active ingredient from being approved until 2027. [1]